 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Gastrointestinal Side Effects of Rofecoxib and Naproxen
7 October 2003 | Volume 139 Issue 7 | Page I-29
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis. A Randomized, Controlled Trial." It is in the 7 October 2003 issue of Annals of Internal Medicine (volume 139, pages 539-546). The authors are J.R. Lisse, M. Perlman, G. Johansson, J.R. Shoemaker, J. Schechtman, C.S. Skalky, M.E. Dixon, A.B. Polis, A.J. Mollen, and G.P. Geba, for the ADVANTAGE Study Group.
What is the problem and what is known about it so far?
Osteoarthritis is a joint disease that gradually wears down cartilage and bone. It is the most common joint disorder worldwide, affecting both men and women as they grow older. Symptoms include pain and stiffness of the fingers and weight-bearing joints, such as the knees, back, and hips. Patients often take medicines, such as naproxen or ibuprofen, to reduce or take away the pain. These medicines are called traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Sometimes, NSAIDs cause gastrointestinal side effects, such as stomach pain, ulcers, or bleeding. More recently developed NSAIDs (called coxibs) are thought to have less frequent and less damaging side effects.
Why did the researchers do this particular study?
To compare the gastrointestinal side effects of rofecoxib and naproxen in patients with osteoarthritis.
Who was studied?
5557 patients with osteoarthritis. Their average age was 63 years. Most had used NSAIDs in the past, many had hypertension, and 13% were taking aspirin to help prevent heart attacks or strokes.
How was the study done?
Patients were randomly assigned to 1 of 2 groups. The first group received rofecoxib, 25 mg once daily, and a dummy pill in the morning and afternoon. The second group received naproxen, 500 mg twice daily, and a dummy pill in the morning. Neither the patients nor their doctors were told who got which treatment. The researchers asked patients about side effects at 3-week intervals during 12 weeks of follow-up. They then compared side effects between groups.
What did the researchers find?
About 6% of the patients taking rofecoxib and 8% of those taking naproxen stopped taking the drugs because of gastrointestinal side effects. Among aspirin users, about 5% taking rofecoxib and 9% taking naproxen stopped taking them. Two patients taking rofecoxib and 9 patients taking naproxen had major problems, such as an ulcer or gastrointestinal bleeding. About 9% of patients taking rofecoxib and about 11% taking naproxen took medicines, such as antacids, to relieve gastrointestinal symptoms.
What were the limitations of the study?
The trial tested daily dosages of drugs for a short period (3 months). Many people with osteoarthritis take drugs intermittently over a long period to relieve symptoms when they have them. Side effects of drugs might be different with intermittent long-term use. Rofecoxib pills typically cost more than naproxen pills. The study did not examine overall health care costs for patients with either drug.
What are the implications of the study?
In older patients with osteoarthritis, rofecoxib causes fewer gastrointestinal side effects than naproxen.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  K. P. Hill, J. S. Ross, D. S. Egilman, and H. M. Krumholz The ADVANTAGE Seeding Trial: A Review of Internal Documents Ann Intern Med, August 19, 2008; 149(4): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox and D. Rennie Seeding Trials: Just Say "No" Ann Intern Med, August 19, 2008; 149(4): 279 - 280. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, K. P. Hill, D. S. Egilman, and H. M. Krumholz Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation JAMA, April 16, 2008; 299(15): 1800 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Letts and J. Loscalzo Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2863 - 2869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. O'Byrne, S. Danson, D. Dunlop, N. Botwood, F. Taguchi, D. Carbone, and M. Ranson Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2007; 25(22): 3266 - 3273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Waksman, A. Brody, and S. D Phillips Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe? Ann. Pharmacother., July 1, 2007; 41(7): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Psaty and R. A. Charo FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part JAMA, May 2, 2007; 297(17): 1917 - 1920. [Full Text] [PDF]
|
|
|
|
|
|
Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gaffo, K. G. Saag, and J. R. Curtis Treatment of rheumatoid arthritis Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2451 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Lippi, M Franchini, G C Guidi, and W F Kean Non-steroidal anti-inflammatory drugs in athletes * Commentary Br. J. Sports Med., August 1, 2006; 40(8): 661 - 663. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rahme, Y. Toubouti, and E. Hunsche Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada Rheumatology, July 1, 2006; 45(7): 903 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Correction: Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, June 20, 2006; 144(12): 943 - 943. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Egilman and A. H. Presler Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, May 16, 2006; 144(10): 781 - 781. [Full Text] [PDF]
|
|
|
|
|
|
C. Laine and C. D. Mulrow Exorcising Ghosts and Unwelcome Guests Ann Intern Med, October 18, 2005; 143(8): 611 - 612. [Full Text] [PDF]
|
|
|
|
|
|
N. Braunstein and A. Polis Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, July 19, 2005; 143(2): 158 - 159. [Full Text] [PDF]
|
|
|
|
 |
|
 T.-J. Aw, S. J. Haas, D. Liew, and H. Krum Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure Arch Intern Med, March 14, 2005; 165(5): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iadecola and P. B. Gorelick The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets Stroke, February 1, 2005; 36(2): 182 - 185. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shah and B. Thomas Nonsteroidal anti-inflammatory analgesics and gastrointestinal protection in palliative care patients Palliative Medicine, December 1, 2004; 18(8): 739 - 740. [PDF]
|
|
|
|
|
|
K. Kroenke and L. Logio Update in General Internal Medicine Ann Intern Med, August 3, 2004; 141(3): 213 - 220. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Hanauer Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Rusche Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1059. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Jenkinson Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stollberger and J. Finsterer Both Thrombotic and Nonthrombotic Cardiovascular and Cerebrovascular Side Effects of Nonsteroidal Anti-Inflammatory Drugs Should Be Considered Stroke, February 1, 2004; 35 (2): e26 - e26. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted: 25 Jul 03 to 7 Nov 03 Evid. Based Nurs., January 1, 2004; 7(1): e1 - 1. [Full Text] [PDF]
|
|
Read all Rapid Responses
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
